Diagnosing Dx

Diagnosing Dx

By Elevra ConsultingScienceLife Sciences
Download on the App Store

Diagnosing Dx episodes

  • Scaling Precision Medicine: Faster Reports, Smarter Trials, Better Care - Garreth Hippe at GenomOncology

    In this episode of Diagnosing Dx, I’m joined by ⁠Garreth Hippe⁠, Chief Commercial Officer at ⁠GenomOncology⁠, a software company helping turn complex genomic data into faster, more actionable decisions in oncology.


    Garreth has spent much of his career in clinical genomics, bioinformatics, and healthcare software, and in this conversation we explore how the field has evolved over the last 20 years, from far slower sequencing workflows to a point where whole genomes can now be analysed in clinically meaningful timeframes. We also unpack how GenomOncology is helping labs bring genomic reporting in-house, reduce turnaround times, ease pressure on molecular pathologists, and match patients to relevant clinical trials before those opportunities are missed.


    A big part of the discussion focuses on AI, not as hype, but as a real force multiplier in healthcare software. Garreth shares how it is accelerating development, improving reporting workflows, and opening up new ways to work with clinical and omics data. We also discuss why genomics is still underused in parts of oncology, where adoption is heading next, and why whole genome sequencing could play a much bigger role in the future of cancer care.


    Key takeaways:


    šŸ”¹ How software is helping translate genomic complexity into clinical action

    šŸ”¹ Why clinical trial matching remains such a critical challenge in oncology

    šŸ”¹ Where AI could have the biggest impact across precision medicine

    šŸ”¹ Why whole genome sequencing may define the future of cancer care


    Chapters:

    00:00 Introduction

    01:56 Garreth Hippe’s background in clinical genomics and software

    03:04 What clinical genomics means: somatic vs germline testing

    05:28 How software in genomics has evolved over the last 20 years

    07:14 AI in healthcare and precision medicine

    09:34 What GenomOncology does and where it fits in the oncology workflow

    15:14 How AI is accelerating product development and lean growth

    20:21 The core problems GenomOncology is solving in reporting and clinical trial matching

    26:10 Company progress, product development, and commercial milestones

    33:46 Adoption challenges in genomics and the future of whole genome sequencing


    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    43 min
  • The Women’s Health Data Gap: Why Diagnostics Are Decades Behind - Marra Francis, MD

    In this first episode of Diagnosing WDx, the new women’s health-focused sister series from Diagnosing Dx, I’m joined by Marra Francis, MD, board-certified OB-GYN, women’s health expert, and advisor to multiple early-stage diagnostics companies.

    Recorded in the week of International Women’s Day, this conversation explores one of the biggest blind spots in healthcare: the historic and ongoing gap in women’s diagnostics.

    Marra breaks down why women were excluded from clinical trials for decades, why many diagnostics and therapeutics still used today were originally studied in men, and why conditions like preeclampsia remain dangerously under-researched. We also explore the role of startups, investors, and AI in helping close the data gap and drive a new era of innovation in women’s health.

    If Diagnosing Dx shines a light on the diagnostics industry, Diagnosing WDx shines a light on the women it has overlooked for far too long.

    Key takeaways:

    šŸ”¹ Why women were historically excluded from clinical research

    šŸ”¹ How gaps in data still affect diagnostics and therapeutics today

    šŸ”¹ Why preeclampsia and autoimmune disease expose major weaknesses in women’s health research

    šŸ”¹ The investment gap holding back progress in women’s diagnostics

    šŸ”¹ Where AI, startups, and new research models could help move the field forward

    Chapters:

    00:00 Introduction

    01:02 Welcome to Diagnosing WDx

    01:53 Marra’s background and path into women’s health diagnostics

    04:49 The real diagnostic gaps women face in clinical practice

    08:05 Marra’s work across women’s health startups and innovation

    11:11 Consumer health, trust, and access to testing

    17:13 The history of women’s exclusion from clinical trials

    20:10 Preeclampsia, autoimmune disease, and the real-world impact of the data gap

    25:41 Why progress in women’s health is still not moving fast enough

    29:22 Diagnostics tested in men and what that means for women today

    32:59 Can AI help close the women’s health data gap?

    42:10 What needs to change next in women’s diagnostics

    47:47 Why Diagnosing WDx matters

    Guest:

    Marra S. Francis

    LinkedIn: https://www.linkedin.com/in/marrasfrancis/

    Resources mentioned:

    1. Women’s Health Initiative

    2. MIT Catalyst Program

    3. For You and Me (FYM)

    4. Nobel Prize in Medicine and Physiology

    Diagnosing WDx is a sister series from Diagnosing Dx, hosted by Elevra Consulting, spotlighting the gaps, opportunities, and innovations shaping the future of women’s diagnostics.

    Learn more: https://elevraconsulting.com/

    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    49 min
  • The $4 Billion Problem in Lyme Diagnostics with Aces Diagnostics

    In this episode of Diagnosing Dx, I’m joined by ⁠Tammy Crawford⁠, Chief Executive Officer, and ⁠Holly Ahern⁠, Chief Scientific Officer at ⁠Aces Diagnostics⁠, a company building what could become the first highly accurate test across all stages of Lyme disease.


    We explore why early Lyme is so often missed, the myth of the bullseye rash, and the structural gaps in today’s testing pathway. Tammy and Holly explain how their personal experiences shaped Aces Diagnostics’ mission and how they’re approaching the problem with a more rigorous, data-driven framework built for real-world adoption.


    This conversation is a grounded look at what it takes to restore confidence in infectious disease diagnostics and why more reliable testing could transform both patient outcomes and healthcare economics.


    Key takeaways:


    šŸ”¹ Why current Lyme diagnostics frequently miss early-stage disease

    šŸ”¹ How combining multiple biomarkers improves diagnostic accuracy

    šŸ”¹ The role of machine learning in interpreting complex immune signatures

    šŸ”¹ Why FDA approval is essential for trust, adoption, and scale


    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    43 min
  • Reimbursement-First Thinking in Early-Stage Diagnostics with OraLiva

    In this episode of Diagnosing Dx, I’m joined by ⁠Spencer Price⁠, Chief Executive Officer at ⁠OraLiva⁠, a company building an AI-powered precision diagnostic designed to transform oral cancer detection and shift the standard of care.


    We explore Spencer’s unconventional move from autonomous vehicles into diagnostics, why OraLiva built commercialisation and reimbursement strategy into the company from day one, and what it really takes to turn breakthrough science into a product that fits seamlessly into clinical workflows. Spencer shares how understanding the healthcare landscape early can shape smarter partnerships, stronger positioning, and long-term scalability.


    This conversation is a grounded look at how diagnostics startups can balance innovation with practicality, building technology that not only works, but gets adopted and paid for.


    Key takeaways:


    šŸ”¹ Why reimbursement strategy needs to start at seed stage

    šŸ”¹ How AI is accelerating preventative diagnostics in oral cancer

    šŸ”¹ The importance of stakeholder engagement across the healthcare ecosystem

    šŸ”¹ Why flexibility and optionality are critical in early-stage diagnostics companies


    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    44 min
  • Building Diagnostics Without Building Hardware: Checktor’s Strategic Play

    In this episode of Diagnosing Dx, I’m joined by Jake Lesinski, Co-founder and CEO of Checktor Biosciences, an ETH Zurich spin-out building a CRISPR-based chemistry platform designed to upgrade existing diagnostic systems rather than replace them.


    We explore why speed, decentralisation, and practical integration, not hype, will define the next wave of molecular diagnostics. Jake shares how Checktor is approaching CRISPR from a clinical and commercial perspective, why matching PCR-level performance matters, and how distribution strategy can make or break even the strongest science.


    This conversation is a grounded look at how diagnostics companies can scale responsibly, partner intelligently, and deliver real value to patients and healthcare systems.


    Key takeaways:


    šŸ”¹ Why rapid, accurate diagnostics remain one of healthcare’s biggest unmet needs

    šŸ”¹ How CRISPR is finally finding its footing in real clinical workflows

    šŸ”¹ Why upgrading existing diagnostic infrastructure beats starting from scratch

    šŸ”¹ What founders need to understand about partnerships, validation, and scale


    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    42 min
  • Why Great Diagnostics Fail: Turning Single-Cell Science Into a Real Product

    In this episode of Diagnosing Dx, I’m joined by Zivjena Vucetic, Chief Medical Officer at Mission Bio, to explore what it really takes to turn breakthrough diagnostics science into tools that change clinical decisions.


    With nearly two decades across oncology, neurology, infectious disease, and single-cell technologies, Zivjena shares a rare perspective on the messy middle of diagnostics, where great science often stalls before reaching patients.


    We dive into why starting with a clinical decision (not the technology) matters, how single-cell multiomics can unlock new insight in complex diseases like AML, and why diagnostics companies must think like product builders to succeed.


    This conversation cuts through the hype to focus on adoption, workflow, validation, and what actually drives impact in modern diagnostics.


    Key takeaways


    šŸ”¹ Why most diagnostics fail on product design and workflow, not science

    šŸ”¹ How single-cell multiomics can reveal clinically meaningful insights in heterogeneous diseases

    šŸ”¹ Why defining the clinical decision and target product profile early is critical

    šŸ”¹ What it really takes to move diagnostics from discovery to standard of care


    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    42 min
  • Why Diagnostic Labs Are Breaking — and How The Proficient Lab Is Fixing It - Unika Alexander

    In this episode of Diagnosing Dx, I’m joined by Unika Alexander, Co-Founder and CEO of The Proficient Lab, to unpack what’s really happening inside today’s diagnostic labs and why many are under more pressure than ever.


    This conversation goes beyond hype to look at the operational reality of diagnostics — from compliance and reimbursement challenges to why modern labs need better data visibility to scale sustainably.


    Key takeaways


    šŸ”¹ Why staffing shortages are one of the biggest operational risks facing labs today

    šŸ”¹ How AI can simplify compliance, audits, and data management — without adding complexity

    šŸ”¹ Why data governance and traceability are critical as labs scale across sites

    šŸ”¹ What diagnostic leaders need to understand about regulation, reimbursement, and efficiency


    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    41 min
  • AGED Dx: Grit, Purpose, and the Fight to Diagnose Liver Disease Early - Rachel Zayas, CEO

    In this episode of Diagnosing Dx, I’m joined by Rachel Zayas, CEO of AGED Diagnostics, a company tackling one of the most underdiagnosed and overlooked conditions in healthcare: liver disease.

    Rachel shares what it really takes to build a diagnostics company from scratch in a high-friction clinical space, why liver disease is so difficult to detect early, and how systemic gaps in specialist access are leaving high-risk patients behind. We also explore the discipline, resilience, and hard lessons that shaped AGED Diagnostics’ mission to diagnose disease earlier—before irreversible damage occurs.

    This conversation is a grounded look at early diagnostics, healthcare bottlenecks, and the realities of building in an area where the need is massive, but the infrastructure is stretched thin.

    Takeaways:

    šŸ”¹ Why liver disease often goes undetected until it’s too late

    šŸ”¹ How non-specific symptoms and specialist shortages delay diagnosis

    šŸ”¹ The lessons learned as a two-time Founding CEO in Diagnostics

    šŸ”¹ What early diagnostics could change for high-risk patients

    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    48 min
  • Head & Neck Cancer Is Still Found Too Late — And OrisDX Is Changing That

    In this episode of Diagnosing Dx, I’m joined by Harald Steltzer, CEO of OrisDX, a company tackling one of the most overlooked gaps in diagnostics: early detection of head and neck cancer. Harald shares his journey from biochemistry and genetics into startup leadership, and why dentistry may be one of the most overlooked frontlines for early cancer detection today. We explore how OrisDX is rethinking diagnostics to reduce clinical friction, improve patient outcomes, and tackle one of healthcare’s hardest problems: reimbursement and adoption. This episode is a focused deep dive into purpose-driven diagnostics, smart go-to-market strategy, and what it really takes to launch a new clinical test in today’s healthcare system. Key takeaways: šŸ”¹ Why head and neck cancer remains under-detected—and how dentistry can change thatšŸ”¹ The role of early detection, education, and digital health in improving outcomesšŸ”¹ How diagnostics founders should think about reimbursement from day onešŸ”¹ What it takes to take a novel diagnostic from concept to clinical launch šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    49 min
  • EXCLUSIVE: Inside VedaBio - The Breakthrough That Could Redefine Point-of-Care Diagnostics

    In this episode of Diagnosing Dx, I sit down with FrĆ©dĆ©ric D. Sweeney, President & CEO of VedaBio, the company pioneering a completely new class of molecular diagnostics — one that detects DNA and RNA without amplification while maintaining full clinical sensitivity in under 10 minutes.

    We explore how this platform could transform urgent care, decentralised testing, and infectious disease workflows — and why VedaBio believes the next leap in molecular diagnostics won’t come from making PCR faster, but from removing amplification entirely.

    FrĆ©dĆ©ric also opens up about the realities of transitioning from feasibility to product development, building the right team, navigating today’s funding climate, and why 2026 is shaping up to be a pivotal year for the company.

    Takeaways:

    šŸ”¹Why removing amplification could reshape point-of-care diagnostics

    šŸ”¹How patient experience drives VedaBio’s product vision

    šŸ”¹The importance of strategic partnerships during early scaling

    šŸ”¹What founders need to know about fundraising and team building in today’s diagnostics market

    šŸ”” Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.

    54 min

About Diagnosing Dx

From the publisher's feed

How do we transform cutting-edge scientific discoveries into life-saving diagnostics?